Molecure Has Signed An Exclusive Licensing Agreement With Ocean Biomedical For Selective YKL-40 Inhibitor Program, Including The Lead Molecule Oat-3912 For Approximately $32M

OAT-3912, which Molecure has developed to early preclinical stage, as well as a second patent for a primary screening test enabling continuation of a continued discovery and development of novel YKL-40 modulators.